GSK gets vaccine deal for Relenza
GSK has won a fairly sizable deal from the federal government in conjunction with all 50 states.
The two-year contract allows 59 jurisdictions to purchase, at a federally negotiated price, up to 15.5 million antiviral treatments and receive a 25 percent federal subsidy.
The contract is part of the HHS program to assure that the country has stockpiles to cover at least 25 percent of the U.S. population in case of a flu pandemic.
This follows in the footsteps of a similar deal with Roche for Tamiflu last year. This is in conjunction with the 44 million treatment courses of Relenza that the government has begun stockpiling without contributions from the states for later distribution in case of a flu pandemic.
[tags]Medicine, pharmacy, GSK, Relenza[/tags]
1 Comment »
RSS feed for comments on this post.
| TrackBack URI
You can also bookmark
this on del.icio.us or check the cosmos
[...] That's pretty sad. I rather hope Gardasil might be a turning point in vaccine marketing and research. I think it might be — vaccines are growing in popularity for all sorts of stuff. [...]
Pingback by When litigation chokes a supply line :: OnThePharm — August 23, 2006 @ 12:08 pm